Key Takeaways
Roth Capital initiates coverage on Pelthos Therapeutics (PTHS) with a ‘Buy’ rating. The price target set by Roth Capital is USD 57.00.Toda
PTHS Gains Analyst Coverage With Roth Capital Initiating at ‘Buy’
Nov 26, 2025
